{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:47:25Z","timestamp":1776091645761,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The clinical and metabolic interactions between hepatitis C virus (HCV) infection and diabetes mellitus (DM) are well documented. The study aimed to compare HCV-infected patients with and without DM. The analysis included 18,968 patients treated with direct-acting antivirals (DAAs) between 2015 and 2023, whose data were collected retrospectively. In the study population, 2179 patients (11.5%) were diagnosed with DM. Compared to the non-diabetic population, they were male-dominated (<jats:italic>p<\/jats:italic>\u2009=\u20090.003), had a significantly higher proportion of patients aged\u2009\u2265\u200950 years (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and were more burdened with comorbidities (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The most common HCV genotype was 1b with a significantly higher prevalence in the diabetic group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Liver disease advancement was higher in diabetic patients, with 17.9% advanced fibrosis and 48% cirrhosis compared to 13.2% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and 21.8% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) in the non-diabetic population. The effectiveness of DAA therapy in patients with DM was significantly lower compared to the population without diabetes, both in intent-to-treat analysis 93.1% vs. 94.6%, <jats:italic>p<\/jats:italic>\u2009=\u20090.015, and per-protocol analysis 96.8% vs. 97.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0128, however, logistic regression analysis did not confirm the role of diabetes as an independent predictor of treatment failure, suggesting that in the absence of other negative prognostic factors, DM alone does not reduce the chances of cure.<\/jats:p>","DOI":"10.1038\/s41598-025-06290-5","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:21:24Z","timestamp":1751383284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes"],"prefix":"10.1038","volume":"15","author":[{"given":"Micha\u0142","family":"Brzd\u0119k","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Rzymski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Lorenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Janocha-Litwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Berak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Tomasiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Sitko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u0142odzimierz","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Janczewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Dybowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Klapaczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Parfieniuk-Kowerda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Jaroszewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Piekarska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"6290_CR1","unstructured":"Hepatitis, C. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"6290_CR2","doi-asserted-by":"publisher","unstructured":"Chen, S. L. & Morgan, T. R. The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 47\u201352. https:\/\/doi.org\/10.7150\/ijms.3.47 (2006).","DOI":"10.7150\/ijms.3.47"},{"key":"6290_CR3","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/v16091386","volume":"16","author":"P Rzymski","year":"2024","unstructured":"Rzymski, P. et al. Like a rolling stone? A review on spontaneous clearance of hepatitis C virus infection. Viruses 16, 1386 (2024).","journal-title":"Viruses"},{"key":"6290_CR4","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","volume":"61","author":"RH Westbrook","year":"2014","unstructured":"Westbrook, R. H. & Dusheiko, G. Natural history of hepatitis C. J. Hepatol. 61, S58\u201368 (2014).","journal-title":"J. Hepatol."},{"key":"6290_CR5","unstructured":"https:\/\/iris.who.int\/bitstream\/handle\/10665\/376461\/9789240091672-eng.pdf?sequence=1."},{"key":"6290_CR6","doi-asserted-by":"publisher","first-page":"e29900","DOI":"10.1002\/jmv.29900","volume":"96","author":"P Rzymski","year":"2024","unstructured":"Rzymski, P. et al. Is there still hope for the prophylactic hepatitis C vaccine? A review of different approaches. J. Med. Virol. 96, e29900 (2024).","journal-title":"J. Med. Virol."},{"key":"6290_CR7","first-page":"3","volume":"3","author":"P Cacoub","year":"2016","unstructured":"Cacoub, P. et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther. Adv. Infect. Dis. 3, 3\u201314 (2016).","journal-title":"Ther. Adv. Infect. Dis."},{"key":"6290_CR8","first-page":"1149","volume":"50","author":"R Nocente","year":"2003","unstructured":"Nocente, R. et al. HCV infection and extrahepatic manifestations. Hepatogastroenterology 50, 1149\u20131154 (2003).","journal-title":"Hepatogastroenterology"},{"key":"6290_CR9","first-page":"65","volume":"16","author":"A Galossi","year":"2007","unstructured":"Galossi, A., Guarisco, R., Bellis, L. & Puoti, C. Extrahepatic manifestations of chronic HCV infection. J. Gastrointestin. Liver Dis. 16, 65\u201373 (2007).","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"6290_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2478\/v10039-010-0009-4","volume":"55","author":"DA Zarebska-Michaluk","year":"2010","unstructured":"Zarebska-Michaluk, D. A., Lebensztejn, D. M., Kryczka, W. M. & Skiba, E. Extrahepatic manifestations associated with chronic hepatitis C infections in Poland. Adv. Med. Sci. 55, 67\u201373 (2010).","journal-title":"Adv. Med. Sci."},{"key":"6290_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4239\/wjd.v5.i1.52","volume":"5","author":"SK Bose","year":"2014","unstructured":"Bose, S. K. Hepatitis C virus infection and insulin resistance. World J. Diabetes 5, 52 (2014).","journal-title":"World J. Diabetes"},{"key":"6290_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/1743-422X-8-474","volume":"8","author":"F Parvaiz","year":"2011","unstructured":"Parvaiz, F. et al. Hepatitis C virus infection: Molecular pathways to insulin resistance. Virol. J. 8, 474 (2011).","journal-title":"Virol. J."},{"key":"6290_CR13","doi-asserted-by":"crossref","unstructured":"Hammerstad, S. S. et al. Diabetes and hepatitis C: A two-way association. Front Endocrinol. (Lausanne) 6 (2015).","DOI":"10.3389\/fendo.2015.00134"},{"key":"6290_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7326\/0003-4819-133-8-200010170-00009","volume":"133","author":"SH Mehta","year":"2000","unstructured":"Mehta, S. H. et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann. Intern. Med. 133, 592\u2013599 (2000).","journal-title":"Ann. Intern. Med."},{"key":"6290_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/jgh.12901","volume":"30","author":"H Rao","year":"2015","unstructured":"Rao, H. et al. CCgenos study group. Prevalence of abnormal glycometabolism in treatment-naive patients with hepatitis C virus infection in a Chinese Han population. J. Gastroenterol. Hepatol. 30, 1049\u20131056 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"6290_CR16","doi-asserted-by":"crossref","unstructured":"Memon, M. S. et al. Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: A southeast Asian study. J. Diabetes Res. 1\u20137 (2013).","DOI":"10.1155\/2013\/539361"},{"key":"6290_CR17","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.3390\/ijms21176275","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia, U. et al. Pathophysiology of type 2 diabetes mellitus. Int. J. Mol. Sci. 21, 6275 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"6290_CR18","doi-asserted-by":"publisher","first-page":"115734","DOI":"10.1016\/j.biopha.2023.115734","volume":"168","author":"SA Antar","year":"2023","unstructured":"Antar, S. A. et al. Diabetes mellitus: classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed. Pharmacother. 168, 115734 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"6290_CR19","unstructured":"Diabetes. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"6290_CR20","first-page":"47","volume":"3","author":"Polish Group of Experts for HCV","year":"2017","unstructured":"Polish Group of Experts for HCV. Recommendations for the treatment of hepatitis C in 2017. Clin. Exp. Hepatol. 3, 47\u201355 (2017).","journal-title":"Clin. Exp. Hepatol."},{"key":"6290_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5114\/ceh.2020.98606","volume":"6","author":"W Halota","year":"2020","unstructured":"Halota, W. et al. Recommendations of the Polish group of experts for HCV for the treatment of hepatitis C in 2020. Clin. Exp. Hepatol. 6, 163\u2013169 (2020).","journal-title":"Clin. Exp. Hepatol."},{"key":"6290_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/ceh.2023.125957","volume":"9","author":"K Tomasiewicz","year":"2023","unstructured":"Tomasiewicz, K. et al. Recommendations of the Polish group of experts for HCV for the treatment of hepatitis C in 2023. Clin. Exp. Hepatol. 9, 1\u20138 (2023).","journal-title":"Clin. Exp. Hepatol."},{"key":"6290_CR23","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, clinical practice guidelines panel: Chair, EASL governing board representative: & panel members: EASL recommendations on treatment of hepatitis C: final update of the series. J. Hepatol. 73, 1170\u20131218 (2020)."},{"key":"6290_CR24","unstructured":"Poland. https:\/\/diabetesatlas.org\/data\/en\/country\/158\/pl.html."},{"key":"6290_CR25","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3748\/wjg.v27.i13.1267","volume":"27","author":"R Chaudhari","year":"2021","unstructured":"Chaudhari, R., Fouda, S., Sainu, A. & Pappachan, J. M. Metabolic complications of hepatitis C virus infection. World J. Gastroenterol. 27, 1267\u20131282 (2021).","journal-title":"World J. Gastroenterol."},{"key":"6290_CR26","unstructured":"Facts & figures. International Diabetes Federation (2022). https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/."},{"key":"6290_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/jcm11020379","volume":"11","author":"P Rajewski","year":"2022","unstructured":"Rajewski, P. et al. HCV genotype has no influence on the incidence of diabetes-EpiTer multicentre study. J. Clin. Med. 11, 379 (2022).","journal-title":"J. Clin. Med."},{"key":"6290_CR28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1186\/s12889-020-08970-5","volume":"20","author":"K Zato\u0144ska","year":"2020","unstructured":"Zato\u0144ska, K. et al. Changes in diabetes prevalence and corresponding risk factors - findings from 3- and 6-year follow-up of PURE Poland cohort study. BMC Public. Health  20, 843 (2020).","journal-title":"BMC Public. Health"},{"key":"6290_CR29","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s00125-023-05891-x","volume":"66","author":"A Kautzky-Willer","year":"2023","unstructured":"Kautzky-Willer, A., Leutner, M. & Harreiter, J. Sex differences in type 2 diabetes. Diabetologia 66, 986\u20131002 (2023).","journal-title":"Diabetologia"},{"key":"6290_CR30","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","volume":"125","author":"JM Hui","year":"2003","unstructured":"Hui, J. M. et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 125, 1695\u20131704 (2003).","journal-title":"Gastroenterology"},{"key":"6290_CR31","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/j.1440-1746.2009.06186.x","volume":"25","author":"CS Hsu","year":"2010","unstructured":"Hsu, C. S. et al. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. J. Gastroenterol. Hepatol. 25, 970\u2013977 (2010).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"6290_CR32","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/hep.27212","volume":"60","author":"YW Huang","year":"2014","unstructured":"Huang, Y. W. et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study. Hepatology 60, 807\u2013814 (2014).","journal-title":"Hepatology"},{"key":"6290_CR33","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/liv.13115","volume":"36","author":"L Elkrief","year":"2016","unstructured":"Elkrief, L. et al. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 36, 936\u2013948 (2016).","journal-title":"Liver Int."},{"key":"6290_CR34","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/gut.2009.179085","volume":"58","author":"N Merchante","year":"2009","unstructured":"Merchante, N. et al. Insulin resistance is associated with liver stiffness in HIV\/HCV co-infected patients. Gut 58, 1654\u20131660 (2009).","journal-title":"Gut"},{"key":"6290_CR35","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1007\/s10620-008-0683-2","volume":"54","author":"HM Elgouhari","year":"2009","unstructured":"Elgouhari, H. M., Zein, C. O., Hanouneh, I., Feldstein, A. E. & Zein, N. N. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig. Dis. Sci. 54, 2699\u20132705 (2009).","journal-title":"Dig. Dis. Sci."},{"key":"6290_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","volume":"4","author":"HB El-Serag","year":"2006","unstructured":"El-Serag, H. B., Hampel, H. & Javadi, F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 4, 369\u2013380 (2006).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"6290_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"K Rao","year":"2011","unstructured":"Rao, K. et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl. J. Med. 364, 829\u2013841 (2011).","journal-title":"N Engl. J. Med."},{"key":"6290_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/ajg.2011.384","volume":"107","author":"SW Lai","year":"2012","unstructured":"Lai, S. W. et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: A population-based cohort study. Am. J. Gastroenterol. 107, 46\u201352 (2012).","journal-title":"Am. J. Gastroenterol."},{"key":"6290_CR39","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.510290235","volume":"29","author":"AL Mason","year":"1999","unstructured":"Mason, A. L. et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29, 328\u2013333 (1999).","journal-title":"Hepatology"},{"key":"6290_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ajg.2023.12.006","volume":"25","author":"RN Marzaban","year":"2024","unstructured":"Marzaban, R. N. et al. Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy. Arab. J. Gastroenterol. 25, 118\u2013124 (2024).","journal-title":"Arab. J. Gastroenterol."},{"key":"6290_CR41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/v14010096","volume":"14","author":"P Pabjan","year":"2022","unstructured":"Pabjan, P. et al. Are there still difficult-to-treat patients with chronic hepatitis C in the era of direct-acting antivirals? Viruses 14, 96 (2022).","journal-title":"Viruses"},{"key":"6290_CR42","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3748\/wjg.v27.i11.1006","volume":"27","author":"D Zar\u0119bska-Michaluk","year":"2021","unstructured":"Zar\u0119bska-Michaluk, D. Genotype 3-hepatitis C virus\u2019 last line of defense. World J. Gastroenterol. 27, 1006\u20131021 (2021).","journal-title":"World J. Gastroenterol."},{"key":"6290_CR43","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3748\/wjg.v29.i6.949","volume":"29","author":"M Brzd\u0119k","year":"2023","unstructured":"Brzd\u0119k, M. et al. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. World J. Gastroenterol. 29, 949\u2013966 (2023).","journal-title":"World J. Gastroenterol."},{"key":"6290_CR44","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.3748\/wjg.v27.i17.1959","volume":"27","author":"M Shengir","year":"2021","unstructured":"Shengir, M., Elgara, M. & Sebastiani, G. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. World J. Gastroenterol. 27, 1959\u20131972 (2021).","journal-title":"World J. Gastroenterol."},{"key":"6290_CR45","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/liv.14031","volume":"39","author":"J Li","year":"2019","unstructured":"Li, J. et al. Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver Int. 39, 1027\u20131032 (2019).","journal-title":"Liver Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06290-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06290-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06290-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:21:28Z","timestamp":1751383288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06290-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6290"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06290-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20936"}}